Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer

Immune checkpoint inhibitor combination therapy exhibited outstanding efficacy in first line setting for advanced non-small cell lung cancer (aNSCLC) patients. However, whether PD-1 inhibitor combined treatment is effective in second line or later setting remains unknown. Therefore, we retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fan, Huang, Di, Li, Tao, Zhang, Sujie, Wang, Jinliang, Zhang, Yuzi, Wang, Guoqiang, Zhao, Zhengyi, Ma, Junxun, Wang, Lijie, Sun, Danyang, Cui, Pengfei, Cai, Shangli, Jiao, Shunchang, Zhao, Lei, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959040/
https://www.ncbi.nlm.nih.gov/pubmed/31942197
http://dx.doi.org/10.7150/jca.37966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959040/
https://www.ncbi.nlm.nih.gov/pubmed/31942197
http://dx.doi.org/10.7150/jca.37966

Ejemplares similares